Skip to content

FULCRUM THERAPEUTICS, INC.

FULC

CIK 0001680581

← back to feed
Revenue (TTM)
—
Q1 Apr 2026
Net Income (TTM)
−$73.44M
−670.0% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$1.12
−637.5% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
—
Q1 Apr 2026
Net Margin
—
Q1 Apr 2026
Free Cash Flow (TTM)
−$83.61M
Q1 Apr 2026
Cash
$50.26M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
66.63M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings